anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND Delivering safe anesthetic care to a patient unable to communicate easily and effectively with the anesthesia team presents many unique challenges. Communication may be limited by language, which can be resolved with translation services, or neurological conditions, such as stroke or traumatic brain injury, which are not easily remedied. In such patients, the inability to communicate effectively can lead to anxiety and negatively impact the patient-anesthesiologist relationship, especially when higher cognitive functions are preserved. CASE REPORT We present a case of a patient with locked-in syndrome (LIS), who presented to our endoscopy unit for a routine colonoscopy. The patient could only communicate with eye movements and blinking, thus limiting our ability to assess their pain or other needs in the perioperative period; however, she was otherwise cognitively intact. By utilizing the patient's home healthcare team and quickly adapting their unique communication methods during the perioperative period, we were able to provide an appropriate, safe anesthetic for this patient with LIS. CONCLUSIONS Many patients requiring an anesthetic are unable to effectively communicate due to language issues, hearing loss/mutism, neurological injury/stroke (aphasia), or developmental disabilities. The unique communication needs of this patient with LIS went beyond utilizing a translator and required the healthcare team to quickly learn a new communication method. We also discuss forms of intraoperative monitoring that can be used to differentiate consciousness from the anesthetized state in LIS patients, as well as making recommendations for future care of such patients.
Tests will be carried out during the afternoon period (between 13.00 and 16.00 h), in a laboratory with an environmental temperature between 22 and 24 ºC and a relative humidity between 44 and 56%.

Each participant will be tested on 3 non-consecutive days. On the first day, a Graded Exercise Testin (GXT) will be performed, to measure VO2max and to enable the individualization of intensities according to the VT of each participant. (Silva et al., 2011). Then, in a randomized (computer generated algorithm) counterbalanced manner, all participants performed resting and standardized cycle-ergometer submaximal protocols on two different conditions (with and without facemask), within a 1-week period. On the first visit, body mass measurements will be taken, to the nearest 0.01 kg, on a digital scale (BG 42, Breuer GmbH, Söflinger, Germany) with the participants wearing light-weight clothes and no shoes. Measurements of standing height will be limited to the first visit and taken to the nearest 0.5 cm using a stadiometer. Body Mass index (BMI) will be calculated by dividing the participants' mass in kilograms by the square of their height in meters. Then, after a brief warm-up period, each participant will perform a maximal cycle-ergometer test consisting of a ramp protocol to volitional exhaustion.

One of our purposes is to determine the impact of exercising with a facemask on physiological recovery. For this reason, measurements, within each submaximal testing session (with and without a facemask), will be taken using a standardized timeline designed to allow measuring recovery postsubmaximal exercise and compare it with a resting baseline time point. Specifically, testing will begin with a 10-min resting period in the seated position (baseline). Subsequently, participants will exercise either without (control) or with (experimental) a surgical facemask at an intensity below the VT and recover for another 10 min. Then, each participant will exercise at an intensity above the VT until volitional exhaustion and this will be followed by 10 min of recovery.
Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm "bites" from the fascial edge and a 1cm "walk" between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected.
BACKGROUND: Ankle osteoarthritis (OA) mainly arises from trauma, particularly lateral ligament injuries. Among lateral ligament injuries, ankles with calcaneofibular ligament (CFL) injuries exhibit increased instability and can be a risk factor ankle OA progression. However, the relationship between CFL injury and OA progression remains unclear. Therefore, this study aims to assess the relationship between CFL injuries and ankle OA by investigating stress changes and osteophyte formation in subtalar joint.
METHODS: We retrospectively reviewed the magnetic resonance imaging (MRI) and plain radiographic evaluations of 100 ankles of 91 patients presenting with chronic ankle instability (CAI), ankle OA, or other ankle conditions. The association between CFL injuries on the oblique view of MRI and the severity of ankle OA (based on Takakura-Tanaka classification) was statistically evaluated. Additionally, 71 ankles were further subjected to CT evaluation to determine the association between the CFL injuries and the Hounsfield unit (HU) ratios of the subtalar joint and medial gutter, and the correlation between the subtalar HU ratios and osteophyte severity were statistically evaluated.
RESULTS: CFL injury was observed in 35.9% (14/39) of patients with stage 0, 42.9% (9/21) with stage 1, 50.0% (10/20) with stage 2, 100% (9/9) with stage 3a, and 90.9% (10/11) with stage 3b. CFL-injured ankles exhibited higher HU ratios in the medial gutter and lower ratios in the medial posterior subtalar joint compared to uninjured ankles. A negative correlation was observed between medial osteophyte severity and the medial subtalar joint HU ratio.
CONCLUSION: Our findings suggest that CFL injuries are common in severe ankle OA impairing the compensatory function of the subtalar joint through abnormal stress distribution and osteophyte formation.
PURPOSE: An anticancer agent containing protein corresponding to kringle KV38 of apolipoprotein(LK8 protein) as an effective ingredient is provided. The LK8 protein has inhibitory capacity against metastasis of cancer cells when systemically administered and an inhibitory effect on the growth of human carcinoma and thus can be used as a cancer metastasis suppressing agent or a therapeutic agent for a primary tumor. CONSTITUTION: An anticancer agent includes LK8 protein described in a sequence number 1. The effective amount of the LK8 protein is 1 to 50mg/kg. Dosing one to four times a day is particularly preferred. It was showed that systemic administration of LK68 causes the inhibition of primary tumor growth, which is correlated with a suppression of tumor-induced angiogenesis. The primary tumor is human prostatic carcinoma and lung carcinoma.
FIELD: polymer production. SUBSTANCE: method involves cationic polymerization of triethylenediamine monomer at heating in presence of catalyst, reaction mixture being preliminarily deaerated in a vacuum at temperature varying from -196 to 150 C. Disintegrated and washed poly-1,4-ethylenepiperazine is added to aqueous solution containing solvent and oxidant capable of forming atomic oxygen under normal conditions, solution being prepared in amounts required for unlimited swelling of polymer and oxidation process being conducted until polymer is entirely dissolved. Poly-1,4-ethylenepiperazine-N-oxyde thus obtained is further subjected to alkylation to give alkyl-derivatives. Polymeric products exhibit physiological and pharmaceutical activities. EFFECT: improved quality and increased yield of desired products according to simplified technology. 12 cl, 2 tbl, 11 ex
PURPOSE:A plaster material capable of stably containing a drug without decomposing it, obtained by blending a plaster material consisting of a pressure- sensitive adhesive substance with root of Cocculus laurifolius A.P. DE CANDOLLE. CONSTITUTION:A plaster material consisting of a pressure-sensitive adhesive substance such as acrylic pressure-sensitive adhesive, rubber pressure-sensitive adhesive, etc., is blended with 0.01-15%, preferably 0.02-2% calculated as fine powder finer than 100 meshes of root of Cocculus laurifolius A.P. DE CANDOLLE, a plant of the family Menispermaceae, used as a vermicide or diuretic in Chinese medicine or 0.002-10%, preferably 0.005-2% calculated as extract with a polar solvent. The plaster material is especially effective for phenolic hydroxyl group-containing compound (e.g. salicylic acid derivative or vitamin E) or amine compound (e.g. ethanolamine antihistamine) showing extreme reduction in content in the existing plaster materials.
Total hip arthroplasty is an effective procedure to improve pain, range of motion, and function for a variety of conditions, including osteoarthritis and posttraumatic arthritis. Up to 28% of patients had persistent pain at the surgical site 12-18 mos after total hip arthroplasty, even in the absence of surgical complications. Currently, there are no widely accepted nonpharmacological treatments for persistent postoperative pain for total hip arthroplasty. This case report details the successful management of a 53-yr-old man with chronic pain and weakness after posttraumatic total hip arthroplasty. He was initially treated with a single-lead percutaneous peripheral nerve stimulator near the right femoral nerve for 4 weeks with 100-Hz frequency sensory-level parameters. Four weeks after implantation, the frequency was changed to 12 Hz with a goal of motor-level stimulation. During the after 3-week time period, his hip flexion strength improved from 10.36 kg to 23.04 kg. His Lower Extremity Functional Scale improved from 35/80 (43.75%) to 54/80 (67.5%) within a 5-wk time period. This case's success demonstrates how peripheral nerve stimulation may help improve postoperative persistent pain and weakness in many patients, including those with posttraumatic arthroplasty.
OBJECTIVE: We conducted a systematic review to assess the scope and effectiveness of interventions to improve human papilloma virus (HPV) vaccination in Africa from 2006 to 2021.
STUDY DESIGN: Systematic review.
METHODS: Four databases (Medline, Embase, CINAHL and PsycINFO) were searched for articles published between 2006 and 2021. Articles were screened and included based on eligibility criteria using DistillerSR (Version 2.35). Data were extracted and reported using a narrative synthesis. A quality assessment was also conducted for each study using validated quality appraisal tools.
RESULTS: Out of 7603 articles identified by a systematic search, 18 articles met the inclusion criteria. Included studies comprised impact evaluation and cross-sectional studies published between 2012 and 2021 and conducted in eight African countries namely: Nigeria, Cameroon, South Africa, Kenya, Tanzania, Zambia, Mali, and Malawi. Study quality ranged from high to low quality. Interventions comprised fifteen educational and three multicomponent interventions. Out of thirteen impact evaluation studies (all educational interventions), twelve studies were effective in increasing HPV vaccine uptake and/or improving participants' knowledge, attitudes, and perceptions about the vaccine. Across five cross-sectional studies (two educational and three multicomponent interventions), HPV vaccine uptake rates ranged from 34% to 93.3%, with a consensus on safety and effectiveness in 67.9%-90.3% of participants post-intervention.
CONCLUSION: Educational and multicomponent interventions have been implemented to improve HPV vaccination in Africa. While educational interventions have proven effective at improving HPV vaccine uptake, a more diverse range of interventions with robust impact evaluation study designs are needed to strengthen the available evidence and improve vaccine uptake.
I:The increase of fat volume dominates. b:The "qod" protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months.
This disclosure relates generally to method and system for estimating smoking episodes from smoke puffs using a wearable device. Since the expense of treating diseases is rising, a digital smoking cessation improves healthcare systems such as cardiovascular issues. To achieve an optimum model given the platform limitations a very compact model is built specifically for the target microcontroller platform. The method of the present disclosure generates an optimum model for deployment on the wearable device using a pretrained deep neural network (DNN). A set of sensor signals are inputted to a convolutional neural network (CNN) smoke detection model to detect smoke puffs. Gesture classifier determines whether the user of the wearable device is engaged/engaging in a smoking session. Further, the method provides users of the wearable device with a cloud estimated smoking behavior analysis based on a set of smoking episodes to generate a set of user risk scores.
OBJECTIVE: To evaluate the sensitivity and ability of computed tomography (CT) scan for diagnosing traumatic ankle arthrotomies compared with that of the saline load test (SLT).
METHODS: Eleven cadaveric ankles were included in this study. Before intervention, a CT scan was obtained to confirm the absence of intra-articular air. Arthrotomies were created at the anterolateral, posterolateral, anteromedial, and posteromedial aspects of the ankle under fluoroscopic visualization. A postarthrotomy and postrange of motion CT scan was obtained to evaluate for the presence of intra-articular air. Each ankle then underwent a SLT with 60 mL of saline, where volumes provoking extravasation were recorded.
RESULTS: Of the 11 included ankles, intra-articular air was detected in all 11 ankles by CT scan. All 11 ankles also demonstrated extravasation of saline through the arthrotomy site during SLT. Thus, the sensitivity for both CT scan and SLT for detecting ankle traumatic arthrotomy was 100%. The mean volume of saline needed for extravasation was 7.7 mL, with a range of 3-22 mL and a SD of 5.4.
CONCLUSIONS: Given that CT scan was equally as sensitive to the SLT, this study presents good evidence that CT scan may be used for the detection of ankle traumatic arthrotomies.
Silicon dioxide (SiO2)-induced pulmonary fibrosis is potentially associated with the impairment of mitochondrial function. Previous research found that inhibition of macrophage receptor with collagenous structure (MARCO) could alleviate particle-induced lung injury by regulating phagocytosis and mitigating mitochondrial damage. The present study aims to explore the underlying anti-fibrosis mechanism of polyguanylic acid (PolyG, MARCO inhibitor) in a silicotic rat model. Hematoxylin and eosin and Masson staining were performed to visualize lung tissue pathological changes. Confocal microscopy, transmission electron microscope, western blot analysis, quantitative real-time PCR (qPCR), and adenosine triphosphate (ATP) content assay were performed to evaluate collagen content, mitochondrial function, and morphology changes in SiO2-induced rat pulmonary fibrosis. The results suggested that SiO2 exposure contributed to reactive oxygen species aggregation and the reduction of respiratory complexes and ATP synthesis. PolyG treatment could effectively reduce MARCO expression and ameliorate lung injury and fibrosis by rectifying the imbalance of mitochondrial respiration and energy synthesis. Furthermore, PolyG could maintain mitochondrial homeostasis by promoting peroxisome proliferator-activated receptor-coactivator 1 α (PGC1α)-mediated mitochondrial biogenesis and regulating fusion and fission. Together, PolyG could ameliorate SiO2-induced pulmonary fibrosis via inhibiting MARCO to protect mitochondrial function.
A method for the treatment and prophylaxis of diseases or conditions associated with aging which includes oxidative stress and cancer. Such diseases or conditions are associated with a decrease or increase presence of one or a combination of one or more Carbonic Anhydrase isozymes I TO VII in the tissue of a subject. These diseases include but are not limited to chronic neurodegenerative diseases such as Alzheimer's disease, parkinson's disease, multiple sclerosis, autism, lou gehrig's disease, huntington's disease, immune disorders which includes systemic lupus erythematosus, diabetes mellitus; musculo-skeletal disorders which includes osteoporosis,arthritis, osteomalacia. Cancer which includes the breast, lung, colon, prostate gland, ovary, esophagus, liver, rectum. The method comprises administering to the patient a pharmaceutically effective non toxic amount of one or a combination of one or more compounds that increases or decreases the level of one or more Cell Specific Carbonic Anhydrase Enzymes whose levels have been increased or decreased in the tissue of the subject. Such compound maybe the Cell Specific Carbonic Anhydrase Enzymes I to VII. A compound that when absorbed reacts or dissociates to form cell specific carbonic enzymes or one or more compounds that when administered promotes the increase or decrease level of one or more cell specific Carbonic anhydrase I,II,III,IV,V,VI,VII. As growth factors of stem cells as an alternative to stem cell therapy. These methods includes the administering of one or a combination of one or more of these compounds over an extended period of time ranging from 6 months until the patient dies.
Chronic pain affects a very high proportion of aging people living with HIV (aPLWH) and is thought to be related to both direct toxicity of HIV and antiretroviral therapy (ART) and by psychosocial factors that negatively affect pain (i.e. loneliness, HIV stigma). PLWH are also at increased risk for prescription opiate misuse. However as PLWH age, non-opiate medications used for pain can contribute to other negative outcomes such as falls, altered mental status and gastrointestinal bleeding. Thus there is a critical need for the development of novel interventions in the management of chronic pain in aPLWH that consider the psychological co-morbidities of aging with HIV and that can minimize the need for prescription medications. Acceptance and commitment therapy (ACT) has previously been evaluated in older persons with chronic pain and has demonstrated higher levels of satisfaction and efficacy when compared to cognitive behavioral therapy (CBT). ACT has never been evaluated in aPLWH for chronic pain, but has theoretical advantages over CBT for this population. Specifically several negatively modifying factors of CBT efficacy such as cognitive deficits are common in aPLWH.

The overarching objective of this study is to determine the acceptability and feasibility of an ACT intervention for the management of chronic pain adapted to aPLWH. To accomplish this objective the investigators will 1) train lay personnel to perform ACT to determine feasibility of this approach for future implementation, 2) conduct uncontrolled group ACT in aPLWH to generate participant feedback and questionnaire data to inform ACT adaption with the assistance of a steering commitee, and 3) conduct a pilot randomized controlled trial (RCT) evaluating the acceptability of adapted ACT compared to pain education. At completion of this grant the investigators expect to have successfully trained lay personnel to perform group ACT, adapted ACT from quantitative and qualitative data collected from an uncontrolled study of group ACT, and determined whether ACT is acceptable and feasible as an intervention in aPLWH. These expected outcomes may benefit other aging populations with chronic pain that are enriched for psychosocial co-morbidities such as persons who inject drugs, the socioeconomically disadvantaged, and racial or gender minorities. This proposal is aligned with the Office of AIDS Research High Priorities to better understand "HIV-associated comorbidities" which includes pain and to "Reduce Health Disparities in treatment outcomes of those living with HIV/AIDS" and with the National Pain Strategy to "expand investment ... in the development of safe and effective pain treatments."
<P>PROBLEM TO BE SOLVED: To provide a method for producing an anthocyanidin peptide derivative which is weak in side effects and has an antiinflammatory effect.  <P>SOLUTION: The anthocyanidin peptide derivative having an antiinflammatory effect refers to a compound in which two molecules of anthocyanidin are combined with phenylalanyl-alanyl-phenylalanyl-valine. Phenylalanine is in the N-terminal position, and valine is in the C-terminal position. The method for producing the anthocyanidin peptide derivative includes the steps of: adding dextrose and lactic acid bacterium to a ground product of black soybean, fermenting the mixture, protecting fermented mash with α-cyclodextrin, digesting the protected mash with protease followed by filtration, treating the resulting filtration residue with cellulase, and extracting the treated residue with ethanol. The anthocyanidin peptide derivative having an antiinflammatory effect is utilized for medicine, cosmetics, daily necessities, and the like.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Various embodiments described herein are directed to compounds of formula (I), (II), (III) or (IV) for use as potent inhibitors of HIV integrase and for treatment of patients afflicted with AIDS. A major challenge of human immunodeficiency virus (HIV) chemotherapy continues to be the inevitable selection of resistance by the virus towards known drug regimens. Treating resistant HIV strains calls for novel antivirals with unique structural cores. Some embodiments are directed to compounds featuring a 3-hydroxypyrimidine-2,4-dione-5-carboxamide core that consistently confers low nanomolar potencies aginst HIV-1 in cell culture. Biochemical testing and molecular modeling results corroborate an antiviral mechanism of action of inhibiting integrase strand transfer (INST). Preliminary testing against raltegravir- resistant HIVs showed marginal cross resistance, suggesting that the chemotypes of the various embodiments described herein could fit an inhibitory profile of second generation INSTIs.
Veterans will be receiving the study medication Nepicastat initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily; During the 8 weeks (weeks: 7-14) extension phase, those from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e. no chance of placebo) treatment and be followed for an additional 8 weeks. Those who have a prior defined positive clinical response to the study medication, Nepicastat, will be continued on open label Nepicastat at 120mg once daily, in order to assess further improvement and safety; those who do not have a positive clinical response during the 6 weeks RCT will be offered the addition of the standard first-line PTSD pharmacotherapy, Paroxetine. Paroxetine is an allowed concomitant medication (i.e. "rescue medication") and is not considered a research medication or subject of a research question during the 8 weeks extension phase.